SLNO · Soleno Therapeutics Inc
$53.01
+0.00 (+0.00%)
At close · May 18
Market Cap
$2.76B
Shares
52.12M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$190.41M
FY2025
Net Income
$20.89M
+111.9%
FY2025
Gross Margin
-4.03%
-46pp
FY2016
Operating Margin
4.94%
FY2025
Diluted EPS
$0.39
+108.9%
FY2025
Operating Cash Flow
$46.8M
+167.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $190.41M | — | — | — | — | — | — | — | — | $1.45M | $607.47K | $0 | $3M | |
| — | $2.7M | — | — | — | — | — | — | — | — | $1.51M | $352.68K | $0 | — | |
| $19.48K | — | — | — | — | — | — | — | — | — | -$58.52K | $254.79K | $0 | — | |
| — | — | — | — | — | — | — | — | — | — | -4.03% | 41.94% | — | — | |
| $38.38M | $40.63M | $78.57M | $25.19M | $15.27M | $21.45M | $23.19M | $16.27M | $7.18M | $3.07M | $2.25M | $4.54M | $2.24M | $2.38M | |
| — | — | — | — | — | — | — | — | — | $26K | $0 | $1.74M | $252.36K | — | |
| — | — | $105.86M | $13.48M | $9.84M | $10.81M | $8.76M | $6.93M | $6.56M | $6.58M | $6.08M | $6.14M | $2.67M | $1.47M | |
| $153.24M | $132.13M | $105.86M | $13.48M | — | — | — | — | — | — | — | — | — | — | |
| $2.03M | $2.02M | $1.99M | $1.96M | $1.96M | $1.96M | $1.95M | $1.96M | $1.96M | $1.61M | $18.67K | $108.23K | $28.52K | $42.11K | |
| $198.57M | $180.99M | $187.67M | $41.38M | $24.4M | $31.53M | $36.29M | $23.49M | $14.3M | $12.17M | $8.32M | $12.41M | $5.16M | $3.85M | |
| $198.57M | $180.99M | $187.67M | $41.38M | — | — | — | — | — | — | — | — | — | — | |
| $86.44M | $9.41M | -$187.67M | -$41.38M | -$24.4M | -$31.53M | -$36.29M | -$23.49M | -$14.3M | -$12.17M | -$8.32M | -$12.16M | -$5.16M | -$846.78K | |
| — | 4.94% | — | — | — | — | — | — | — | — | -573.77% | -2001.7% | — | -28.23% | |
| $88.46M | $11.43M | -$185.68M | -$39.43M | -$22.43M | -$29.57M | -$34.34M | -$21.53M | -$12.34M | -$10.56M | -$8.31M | -$12.05M | -$5.13M | -$804.67K | |
| $5.41M | $5.48M | $231K | $0 | $0 | — | — | — | — | — | — | $0 | $4.13M | $2.86M | |
| $18.55M | $16.95M | $12.05M | $2.58M | $300K | — | — | — | — | — | — | $0 | $1085 | $1772 | |
| $13.14M | $11.48M | $11.82M | $2.4M | $330K | $618K | $11.65M | -$7.29M | $2.46M | -$1.27M | $1.59M | -$3.75M | -$3.95M | -$1965 | |
| — | — | — | — | — | — | — | -$478K | -$160K | — | — | — | — | — | |
| — | $20.89M | -$175.85M | -$38.99M | -$24.07M | -$30.91M | -$24.64M | -$30.77M | -$11.84M | -$13.44M | -$6.74M | -$15.91M | — | — | |
| — | $0 | $0 | $0 | — | — | — | — | $0 | -$1.65M | $0 | $0 | $0 | $0 | |
| $96.04M | $20.89M | -$175.85M | -$38.99M | -$24.07M | -$30.91M | -$24.64M | -$30.77M | -$13.34M | -$15.39M | -$12.07M | -$15.91M | -$13.24M | -$3.71M | |
| — | 10.97% | — | — | — | — | — | — | — | — | -831.63% | -2618.81% | — | -123.57% | |
| — | $20.48M | -$175.85M | -$38.99M | — | — | — | — | — | -$15.67M | -$15.72M | -$15.91M | — | — | |
| $93.98M | $20.94M | -$175.49M | -$38.99M | -$24.07M | — | — | — | — | — | — | — | — | — | |
| USD/shares | — | $0.40 | -$4.38 | -$2.36 | -$2.87 | -$5.81 | — | — | — | — | — | — | — | — |
| USD/shares | — | $0.39 | -$4.38 | -$2.36 | -$2.87 | -$5.81 | — | — | — | — | — | — | — | — |
| shares | — | 50.82M | 40.18M | 16.49M | 8.4M | 5.32M | 4.17M | 2.28M | 1.4M | 598.52K | 206.77K | 628.39K | 84.67K | 35.71K |
| shares | — | 52.38M | 40.18M | 16.49M | 8.4M | 5.32M | 4.17M | 2.28M | 1.4M | 598.52K | 206.77K | 628.39K | 84.67K | 35.71K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2025: $100.15M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.78×
EV/EBIT
—
Peer median 17.94×
P/E (TTM)
27.47×
Peer median 18.28×
Peer medians compare against the 227 similar-size Biotechnology companies (of 522 listed).